What is calcort?
Calcort is a brand name formulation of deflazacort, a synthetic glucocorticoid corticosteroid medication that is used for its potent anti-inflammatory and immunosuppressive properties. Deflazacort is an oxazoline derivative of prednisolone and is classified as an intermediate-acting glucocorticoid. It was developed with the goal of providing effective anti-inflammatory activity while potentially offering a more favorable side effect profile compared to traditional corticosteroids such as prednisone and prednisolone. Calcort has been available in various countries for several decades and has been used for many inflammatory and autoimmune conditions.
Deflazacort is a prodrug that undergoes rapid and extensive metabolism in the body to its active metabolite, 21-desacetyl deflazacort, which is responsible for the pharmacological activity of the drug. The conversion occurs primarily in the liver and plasma following oral administration. The active metabolite binds to the glucocorticoid receptor and exerts the classical genomic effects of corticosteroids, including the modulation of gene transcription that leads to the suppression of inflammatory mediators and the upregulation of anti-inflammatory proteins. Calcort is available in tablet form in various strengths and is typically administered orally once daily, which provides convenience for patients requiring long-term corticosteroid therapy.
One of the distinguishing features attributed to deflazacort is its potential for a reduced incidence of certain adverse effects, particularly those related to glucose metabolism, electrolyte balance, and bone metabolism, when compared with equipotent doses of other corticosteroids. This reputed “steroid-sparing” effect has been attributed to differences in the molecular structure and perhaps to differences in the metabolism and tissue distribution of the drug. However, it is important to recognize that deflazacort, like all corticosteroids, can produce the full spectrum of glucocorticoid adverse effects when used at high doses or for prolonged periods, and the evidence for clinically meaningful differences in the safety profile compared with other corticosteroids has been debated in the medical literature.
How does calcort work?
The mechanism of action of deflazacort, the active pharmaceutical ingredient in Calcort, follows the classical pathway of glucocorticoid receptor-mediated effects on gene expression. After oral administration, deflazacort is rapidly metabolized to 21-desacetyl deflazacort, which is the active moiety that mediates the pharmacological effects. This active metabolite enters target cells by passive diffusion across the cell membrane and binds to the cytoplasmic glucocorticoid receptor. The glucocorticoid receptor is a member of the nuclear receptor superfamily of ligand-activated transcription factors and is expressed in virtually all cell types throughout the body.
In the absence of ligand, the glucocorticoid receptor resides in the cytoplasm in a complex with heat shock proteins and other chaperone proteins that maintain the receptor in an inactive conformation. Upon binding of the active metabolite of deflazacort, the receptor undergoes a conformational change that releases it from the chaperone complex and exposes nuclear localization signals that direct the receptor-ligand complex to translocate into the nucleus. This translocation occurs within minutes of ligand binding and is an energy-dependent process that utilizes the cellular transport machinery.
Once inside the nucleus, the activated glucocorticoid receptor complex exerts its effects on gene expression through two primary mechanisms: transactivation and transrepression. In transactivation, the receptor-ligand complex binds as a homodimer to specific DNA sequences known as glucocorticoid response elements located in the promoter regions of target genes. This binding recruits coactivator proteins and the transcriptional machinery, leading to increased transcription of genes encoding anti-inflammatory proteins such as annexin A1, interleukin-10, and the inhibitor of nuclear factor kappa B. These proteins mediate the anti-inflammatory and immunosuppressive effects of corticosteroids.
In transrepression, the activated glucocorticoid receptor interferes with the activity of other transcription factors that promote the expression of pro-inflammatory genes. The most important of these interactions involves the inhibition of nuclear factor kappa B and activator protein-1, two transcription factors that are central to the coordinated expression of numerous genes encoding pro-inflammatory cytokines, chemokines, adhesion molecules, and enzymes such as cyclooxygenase-2 and inducible nitric oxide synthase. The glucocorticoid receptor inhibits these transcription factors through protein-protein interactions that prevent their binding to DNA or their ability to activate transcription, and by recruiting histone deacetylases that modify chromatin structure and suppress gene expression. This transrepression mechanism is thought to underlie many of the anti-inflammatory effects of corticosteroids.
The net effect of these nuclear actions of the activated glucocorticoid receptor is the suppression of the inflammatory response at multiple levels. The production of pro-inflammatory cytokines such as interleukin-1, interleukin-6, and tumor necrosis factor-alpha is reduced. The expression of adhesion molecules on endothelial cells, which is essential for the recruitment of leukocytes to sites of inflammation, is decreased. The activity of inflammatory cells including neutrophils, macrophages, and lymphocytes is inhibited. The production of inflammatory mediators including prostaglandins and leukotrienes is suppressed. Collectively, these effects result in a deep reduction in the cardinal signs of inflammation: redness, swelling, heat, pain, and loss of function.
Indications and uses of calcort
Calcort is indicated for the treatment of a wide variety of inflammatory, allergic, and autoimmune conditions in which corticosteroid therapy is clinically indicated. The breadth of indications for deflazacort reflects ubiquity of the glucocorticoid receptor and the diverse clinical manifestations of inflammation across different organ systems. The decision to use Calcort, like any corticosteroid, should be based on a careful assessment of the potential benefits of therapy weighed against the known risks of corticosteroid treatment, and the lowest effective dose should be used for the shortest possible duration.
Musculoskeletal and rheumatologic disorders
Calcort is commonly used for various rheumatologic and musculoskeletal conditions characterized by inflammation. Rheumatoid arthritis, a chronic autoimmune inflammatory disorder primarily affecting the synovial joints, is one of the most frequent indications for corticosteroid therapy. In rheumatoid arthritis, Calcort can provide rapid relief of joint pain and swelling while disease-modifying antirheumatic drugs are being initiated and titrated to therapeutic effect. Corticosteroids may also be used as long-term low-dose therapy for patients with persistently active disease despite optimal treatment with other agents.
Other rheumatologic conditions for which Calcort may be prescribed include systemic lupus erythematosus, polymyalgia rheumatica, giant cell arteritis, polymyositis and dermatomyositis, and various forms of vasculitis. In many of these conditions, corticosteroids are the foundation of initial therapy and may be required for the acute management of severe or life-threatening manifestations. Calcort may also be used for acute gouty arthritis and pseudogout, particularly when nonsteroidal anti-inflammatory drugs are contraindicated or ineffective.
Respiratory conditions
Asthma is one of the most common indications for corticosteroid therapy, and Calcort may be used for the management of acute asthma exacerbations and for the long-term control of severe persistent asthma that is not adequately controlled with inhaled corticosteroids and other controller medications. The anti-inflammatory effects of corticosteroids are particularly important in asthma, as airway inflammation is a central feature of the disease and contributes to airway hyperresponsiveness, mucus hypersecretion, and airway remodeling.
Chronic obstructive pulmonary disease is another respiratory condition for which oral corticosteroids may be prescribed, particularly during acute exacerbations. A short course of Calcort can accelerate the resolution of symptoms and improve lung function in patients experiencing an exacerbation of chronic obstructive pulmonary disease. Other respiratory indications for corticosteroid therapy include allergic rhinitis, particularly seasonal or perennial forms that are not adequately controlled with intranasal corticosteroids and antihistamines, and various interstitial lung diseases including sarcoidosis, hypersensitivity pneumonitis, and idiopathic pulmonary fibrosis.
Dermatologic conditions
A wide range of dermatologic conditions may be treated with Calcort. These include severe acute or chronic allergic contact dermatitis, atopic dermatitis that is refractory to topical therapies, pemphigus vulgaris, bullous pemphigoid, severe psoriasis, erythema multiforme, lichen planus, and various forms of cutaneous vasculitis. In dermatology, systemic corticosteroids are generally reserved for severe or extensive disease that cannot be adequately managed with topical agents alone, or for conditions that are known to require systemic immunosuppression for disease control.
Other indications
The therapeutic applications of Calcort extend beyond the major categories described above. In gastroenterology, corticosteroids are used for inflammatory bowel disease, including ulcerative colitis and Crohn disease, particularly during acute exacerbations. In neurology, corticosteroids are employed for the acute treatment of multiple sclerosis relapses and for the management of cerebral edema associated with brain tumors. In ophthalmology, systemic corticosteroids are used for the treatment of various inflammatory conditions of the eye, including uveitis, optic neuritis, and thyroid eye disease. In oncology, corticosteroids are used as part of chemotherapy regimens for certain hematologic malignancies and for the management of tumor-related edema and other complications. In the perioperative setting, corticosteroids may be administered for the prevention of postoperative nausea and vomiting and for their anti-inflammatory effects.
Dosage and administration
The dosage of Calcort must be individualized based on the specific condition being treated, the severity of the disease, the anticipated duration of therapy, and the patient’s response and tolerability. The goal of corticosteroid dosing is to achieve control of the disease process with the lowest effective dose administered for the shortest necessary duration. The tablet strengths of Calcort typically include six milligrams, eighteen milligrams, thirty milligrams, and sixty milligrams.
For most inflammatory conditions, the initial dose of Calcort for adults may range from six to ninety milligrams per day, depending on the severity of the disease and the clinical urgency of achieving symptom control. Doses at the higher end of this range are typically used for acute, severe exacerbations of inflammatory conditions or for the initial management of life-threatening manifestations of autoimmune diseases. Once clinical improvement is achieved, the dose should be gradually tapered to the lowest level that maintains disease control. The tapering schedule must be individualized and may need to be adjusted based on the patient’s clinical response and the development of any adverse effects.
Alternate-day dosing
For patients requiring long-term corticosteroid therapy, alternate-day dosing may be considered as a strategy to reduce the risk of certain adverse effects while maintaining therapeutic benefit. In this approach, the total daily dose that would otherwise be administered is doubled and given as a single dose every other morning, ideally at around eight in the morning to coincide with the natural circadian peak in endogenous cortisol secretion. Alternate-day dosing may reduce the suppression of the hypothalamic-pituitary-adrenal axis and may be associated with a lower incidence of growth suppression in children and certain metabolic effects in adults. However, not all conditions can be adequately controlled with alternate-day dosing, and some patients may experience a recrudescence of symptoms on the off day.
Discontinuation and tapering
Abrupt discontinuation of Calcort after prolonged therapy can result in acute adrenal insufficiency, a potentially life-threatening condition resulting from suppression of the hypothalamic-pituitary-adrenal axis. The duration and dose of corticosteroid therapy that can produce clinically significant adrenal suppression vary among patients, but suppression should be assumed after two to three weeks of therapy with doses equivalent to or exceeding the physiological replacement dose. The risk of adrenal insufficiency persists for months after corticosteroid discontinuation and may be unmasked by the stress of illness, injury, or surgery.
To minimize the risk of withdrawal symptoms and adrenal insufficiency, the dose of Calcort should be tapered gradually when it is determined that corticosteroid therapy should be discontinued. The rate of taper depends on the dose and duration of therapy, the underlying disease, and the individual patient’s clinical status. A typical tapering schedule may involve reducing the daily dose by increments of two and a half to five milligrams of prednisolone equivalent every one to two weeks. More rapid tapering may be appropriate for patients who have received only short courses of therapy. The need for supplemental corticosteroid coverage during periods of stress should be considered for patients who have been on long-term therapy, even after the medication has been discontinued.
Side effects of calcort
The adverse effect profile of Calcort encompasses the full spectrum of glucocorticoid toxicities that are well recognized with all corticosteroid medications. The likelihood and severity of adverse effects are related to the dose and duration of therapy, with higher doses and longer durations associated with greater risk. Individual patient susceptibility to specific adverse effects varies and may be influenced by genetic factors, age, comorbidities, and the concomitant use of other medications.
Musculoskeletal effects
Osteoporosis is one of the most important long-term complications of corticosteroid therapy. Corticosteroids reduce bone formation by inhibiting osteoblast function and promoting osteoblast apoptosis, while also increasing bone resorption through effects on the regulation of calcium metabolism. The result is a net loss of bone mass, particularly in trabecular bone, which increases the risk of fractures. The risk of fracture is related to the cumulative dose of corticosteroid received and is most pronounced in postmenopausal women and elderly patients. All patients who are anticipated to receive corticosteroids for three months or longer should be considered for bone density measurement and should receive appropriate preventive measures, including adequate calcium and vitamin D supplementation and, for those at increased risk, bisphosphonate therapy.
Myopathy, characterized by proximal muscle weakness and wasting, can occur with prolonged corticosteroid therapy. This effect is particularly notable with fluorinated corticosteroids such as dexamethasone and triamcinolone, but can also occur with deflazacort. The myopathy typically affects the proximal muscles of the upper and lower extremities, resulting in difficulty rising from a chair, climbing stairs, or lifting objects overhead. Corticosteroid-induced myopathy is generally reversible upon dose reduction or discontinuation of the drug, but recovery may take weeks to months. Avascular necrosis of bone, also known as osteonecrosis, is a serious complication that most commonly affects the femoral head but can also occur in other bones. The risk factors for avascular necrosis include high-dose corticosteroid therapy, and the condition should be considered in any patient on corticosteroids who develops new joint pain, particularly in the hip, groin, or knee.
Endocrine and metabolic effects
Hyperglycemia is a well-recognized metabolic effect of corticosteroids. Corticosteroids increase hepatic glucose production and reduce peripheral glucose uptake, leading to elevated blood glucose levels. In patients with pre-existing diabetes mellitus, corticosteroid therapy can exacerbate hyperglycemia and increase insulin requirements. In susceptible individuals without a prior diagnosis of diabetes, corticosteroid therapy can unmask latent diabetes or precipitate steroid-induced diabetes. Blood glucose monitoring is recommended for all patients receiving moderate to high doses of corticosteroids, and antidiabetic therapy should be initiated or adjusted as needed.
Weight gain and the development of cushingoid features are common with prolonged corticosteroid therapy. Cushingoid features include moon facies, supraclavicular and dorsocervical fat pads, truncal obesity, and thin skin with easy bruisability. These physical changes can cause significant psychological distress for patients and may affect self-esteem and body image. The redistribution of body fat characteristic of exogenous Cushing syndrome is generally reversible upon dose reduction or discontinuation of corticosteroids, but complete resolution may take months. Suppression of the hypothalamic-pituitary-adrenal axis is a universal consequence of supraphysiologic corticosteroid therapy and requires attention to tapering of the drug dose and the provision of stress-dose corticosteroid coverage as needed.
Cardiovascular effects
Hypertension can develop or be exacerbated during corticosteroid therapy. The mechanisms involve sodium and fluid retention, increased vascular sensitivity to vasoconstrictors, and direct effects on vascular smooth muscle. Blood pressure should be monitored regularly in patients receiving corticosteroids, and antihypertensive therapy should be initiated or adjusted as needed to achieve blood pressure goals. Fluid retention can also contribute to the development or worsening of congestive heart failure in susceptible patients, and corticosteroids should be used with caution in individuals with impaired cardiac function.
Electrolyte imbalances are another potential adverse effect of corticosteroid therapy. Sodium retention and potassium loss can occur, particularly with corticosteroids that have significant mineralocorticoid activity. While deflazacort is reported to have less mineralocorticoid activity than prednisolone and other traditional corticosteroids, electrolyte disturbances can still occur, especially at higher doses. Serum electrolytes should be monitored in patients receiving long-term corticosteroid therapy, and potassium supplementation may be necessary in those who develop hypokalemia.
Dermatologic effects
Skin atrophy, manifested as thinning and fragility of the skin with easy bruising and poor wound healing, is a common consequence of corticosteroid therapy. The mechanisms involve inhibition of fibroblast proliferation and collagen synthesis, and reduction in the synthesis of other components of the extracellular matrix. Patients should be counseled about the increased susceptibility to bruising and skin tears and should be advised to protect their skin from trauma. Acne, striae, and hirsutism are other dermatologic effects that may occur. Impaired wound healing is of particular concern in the perioperative setting and in patients with chronic wounds or ulcers.
Gastrointestinal effects
Peptic ulcer disease has historically been attributed to corticosteroid therapy, although the evidence for a causal relationship is not as strong as once believed. The risk of peptic ulcer disease appears to be increased when corticosteroids are used in combination with nonsteroidal anti-inflammatory drugs, and the concomitant use of these two classes of medications should be undertaken with caution. Gastrointestinal prophylaxis with proton pump inhibitors or other acid-suppressing medications should be considered for patients receiving both corticosteroids and nonsteroidal anti-inflammatory drugs. Other gastrointestinal effects of corticosteroids may include nausea, increased appetite, and pancreatitis.
Visit Happy Family Pharmacy for more information on Calcort
Precautions and warnings
Immunosuppression and infection risk
Corticosteroids suppress the immune system at multiple levels, and patients receiving these medications are at increased risk for infections caused by many pathogens. The risk of infection increases with the dose and duration of corticosteroid therapy. Patients should be counseled about the increased susceptibility to infection and should be instructed to report any signs or symptoms of infection, including fever, cough, sore throat, or wound drainage, to their healthcare provider promptly. The administration of live or live-attenuated vaccines should be avoided in patients receiving immunosuppressive doses of corticosteroids, as the immune response to the vaccine may be blunted and the risk of vaccine-associated infection may be increased.
Certain infections, such as tuberculosis, strongyloidiasis, and herpes zoster, may be reactivated in patients receiving corticosteroids. Before initiating prolonged corticosteroid therapy, patients should be evaluated for evidence of latent tuberculosis infection, and appropriate prophylactic therapy should be administered to those with latent infection. The use of corticosteroids in patients with known or suspected fungal infections should generally be avoided, as the immunosuppressive effects of corticosteroids can promote the dissemination of fungal disease.
Ocular effects
Posterior subcapsular cataracts and glaucoma are well-recognized complications of long-term corticosteroid therapy, whether administered systemically or topically to the eye. The risk of these complications increases with the dose and duration of therapy. Patients receiving prolonged corticosteroid therapy should undergo periodic ophthalmologic examinations to screen for the development of cataracts and to monitor intraocular pressure. Corticosteroid-induced glaucoma results from increased resistance to aqueous humor outflow and can lead to irreversible optic nerve damage if not detected and treated in a timely manner. Patients with a family history of glaucoma or other risk factors may be at particularly increased risk.
Psychiatric effects
Corticosteroids can produce many psychiatric effects, including mood elevation, euphoria, and increased energy at one end of the spectrum to depression, anxiety, and psychosis at the other. The risk of psychiatric effects is dose-dependent and is increased in patients with a history of psychiatric illness. Patients and their families should be educated about the potential for mood and behavioral changes and should be advised to report any concerning psychological symptoms to the healthcare provider. Most psychiatric effects are reversible upon dose reduction or discontinuation of the corticosteroid.
Pregnancy and lactation
Calcort should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Corticosteroids can cross the placenta, and exposure during pregnancy has been associated with a small increase in the risk of oral clefts. Pregnant women receiving long-term corticosteroid therapy should be monitored for the development of gestational diabetes and hypertension. Neonates exposed to corticosteroids in utero should be observed for evidence of adrenal insufficiency. Corticosteroids are excreted in breast milk in small amounts, and caution is advised when Calcort is administered to nursing mothers.
Drug interactions
The potential for drug interactions with deflazacort is significant and reflects pathways involved in the metabolism and disposition of the drug. Deflazacort is metabolized to its active metabolite, 21-desacetyl deflazacort, by plasma esterases, and the active metabolite is further metabolized by the cytochrome P450 enzyme system, particularly CYP3A4. Drugs that induce or inhibit CYP3A4 can affect the clearance of the active metabolite and alter the pharmacologic effect and toxicity profile of Calcort.
Inducers of CYP3A4, such as rifampin, phenytoin, phenobarbital, and carbamazepine, can increase the clearance of deflazacort and reduce its therapeutic effect. Patients receiving these drugs concurrently with Calcort may require higher doses of the corticosteroid to achieve the desired clinical response, and the dose of Calcort may need to be reduced when the inducing agent is discontinued. Inhibitors of CYP3A4, such as clarithromycin, itraconazole, ketoconazole, and ritonavir, can decrease the clearance of deflazacort and increase the risk of corticosteroid toxicity. Dose reduction may be necessary when Calcort is coadministered with potent CYP3A4 inhibitors.
Pharmacodynamic interactions are also important to consider when prescribing Calcort. The concurrent use of Calcort with other medications that can cause gastrointestinal irritation, such as nonsteroidal anti-inflammatory drugs, increases the risk of peptic ulcer disease and gastrointestinal bleeding. The combination of corticosteroids with other immunosuppressive agents may increase the overall degree of immunosuppression and the risk of infection. Corticosteroids can reduce the effectiveness of antihypertensive and antidiabetic medications, and doses of these drugs may need to be increased during corticosteroid therapy.
Storage and handling
Calcort tablets should be stored at controlled room temperature, typically between twenty and twenty-five degrees Celsius, in a dry place protected from light and moisture. The medication should be kept in its original packaging and stored out of the reach of children. Patients should be advised not to use Calcort beyond the expiration date printed on the packaging. Unused or expired medication should be disposed of safely, following local guidelines for pharmaceutical waste disposal. Patients should be reminded not to share their medication with others, as the prescription is based on their individual medical condition and the use of corticosteroids by individuals without a medical indication can be associated with significant adverse effects.
Frequently asked questions about calcort
How is calcort different from prednisone?
Calcort contains deflazacort, which is an oxazoline derivative of prednisolone. Both medications are corticosteroids with anti-inflammatory and immunosuppressive properties. Deflazacort is sometimes described as having a more favorable side effect profile, with potentially less impact on glucose metabolism, bone density, and electrolyte balance compared to equipotent doses of prednisone. However, both medications share the same fundamental mechanism of action and can produce the same spectrum of corticosteroid adverse effects. The choice between Calcort and prednisone depends on various factors, including the specific condition being treated, the patient’s comorbidities and risk factors for adverse effects, the clinical experience of the prescribing physician, and the availability and cost of the medications.
Can i stop taking calcort suddenly?
No, Calcort should not be stopped suddenly if you have been taking it for more than a few weeks at doses above the physiological replacement level. Abrupt discontinuation can result in symptoms of adrenal insufficiency, including fatigue, weakness, dizziness, nausea, vomiting, and low blood pressure. In severe cases, acute adrenal insufficiency can be life-threatening. Also, the underlying condition for which the corticosteroid was prescribed may flare if the medication is stopped abruptly. The dose of Calcort should always be tapered gradually under the supervision of a healthcare provider who can provide a tapering schedule and monitor for the development of withdrawal symptoms or disease exacerbation.
What precautions should i take while on long-term calcort therapy?
Patients on long-term Calcort therapy should be followed regularly by their healthcare provider. Important aspects of monitoring include periodic assessment of blood pressure, blood glucose, serum electrolytes, bone density, and ophthalmologic examination. Patients should be counseled about the importance of adequate calcium and vitamin D intake for bone health. They should be advised to report any signs of infection, unusual bruising or bleeding, changes in vision, or new psychological symptoms to their healthcare provider. Patients should wear a medical alert bracelet or carry a card indicating that they are taking corticosteroids, as this information may be critical in the event of a medical emergency. Lifestyle measures such as a healthy diet, regular exercise within individual limitations, and avoidance of smoking and excessive alcohol consumption can help reduce the risk of some corticosteroid-associated adverse effects.
Summary
Calcort, containing the active ingredient deflazacort, is a synthetic glucocorticoid corticosteroid used for its anti-inflammatory and immunosuppressive effects in a wide variety of conditions, including rheumatologic disorders, respiratory diseases, dermatologic conditions, and other inflammatory and autoimmune diseases. Deflazacort is a prodrug that is rapidly metabolized to its active metabolite, 21-desacetyl deflazacort, which binds to the glucocorticoid receptor and modulates gene expression through transactivation and transrepression mechanisms, resulting in the suppression of inflammatory mediators and the upregulation of anti-inflammatory proteins.
The dosage of Calcort must be individualized, with the goal of using the lowest effective dose for the shortest possible duration. Long-term therapy requires gradual tapering to avoid adrenal insufficiency, and alternate-day dosing may be considered as a steroid-sparing strategy. The adverse effect profile of Calcort is characteristic of all corticosteroids and includes osteoporosis, hyperglycemia, weight gain, cushingoid features, immunosuppression, hypertension, psychiatric effects, cataracts, and glaucoma. The risk of these effects increases with higher doses and longer durations of therapy. Numerous drug interactions must be considered when prescribing Calcort, particularly those mediated through the CYP3A4 enzyme system.
Appropriate patient education regarding the proper use of the medication, the importance of adherence to the prescribed dosing and tapering schedules, the recognition of adverse effects, and the need for regular monitoring is essential for safe and effective therapy. When prescribed with appropriate attention to dosing, monitoring, and prevention and management of adverse effects, Calcort provides effective corticosteroid therapy for many inflammatory and autoimmune conditions.